1.127EUR-0.88%Mkt Cap: 783.23M EURP/E: 55.45Last update: 2026-05-14
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)55.45
P/E (Forward)35.88
PEG—
P/B3.29
P/S2.12
EV/EBITDA18.26
EV/Revenue2.09
EPS (TTM)0.02
EPS (Forward)0.03
Cash Flow & Leverage
FCF Yield7.54%
FCF Margin15.97%
Operating CF54.71M EUR
CapEx (TTM)755.00K EUR
Net Debt/EBITDA-1.28
Net Debt-53.97M EUR
Technical
SMA 501.374 (-18.0%)
SMA 2001.350 (-16.5%)
Beta0.12
S&P 52W Chg24.23%
Avg Vol (30d)13.41M
Avg Vol (10d)19.43M
Technical Indicators
RSI (14)30.0
MACD-0.0849
MACD Signal-0.0524
MACD Hist.-0.0325
BB Upper1.662 EUR
BB Middle1.338 EUR
BB Lower1.014 EUR
BB Width48.39%
ATR (14)0.0645 EUR
Vol Ratio (20d)0.52x
52W Range
0.838029% of range1.818
52W High1.818 EUR
52W Low0.8380 EUR
Profitability
Gross Margin87.90%
EBITDA Margin11.44%
Profit Margin0.76%
Oper. Margin-6.78%
ROE1.03%
ROA0.57%
Revenue Growth-8.40%
Earnings Growth—
Balance Sheet
Debt/Equity0.42
Current Ratio2.63
Quick Ratio2.05
Book Value/Sh0.3370 EUR
Cash/Share0.2290 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 5, 2013
Ownership
Shares Out.706.25M
Float733.15M
Insiders1.89%
Institutions22.73%
Analyst Consensus
Rating—
Target (Mean)2.231 EUR
Target Range1.901 EUR – 2.615 EUR
# Analysts4
Company
Market Cap783.23M EUR
Enterprise Value771.92M EUR
Revenue (TTM)369.49M EUR
Gross Profit330.63M EUR
Net Income (TTM)2.85M EUR
Revenue/Share0.5220 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees407
Last Price1.127 EUR
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL0010391025